<DOC>
	<DOC>NCT00843284</DOC>
	<brief_summary>A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.</brief_summary>
	<brief_title>Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA</brief_title>
	<detailed_description>A non-interventional study of patients diagnosed with neuropathic pain administered pregabalin and followed up for 8 weeks</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics. The patients were excluded according to the current Summary of Product Characteristics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>neuropathic, pain, pregabalin, Lyrica</keyword>
</DOC>